阿普米司特治疗难治性银屑病合并4期慢性肾脏病患者1例疗效观察

doi:10.35541/cjd.20230580

Chinese Journal of Dermatology ›› 2024, Vol. 57 ›› Issue (9): 844-845.doi: 10.35541/cjd.20230580

• Case Reports • Previous Articles Next Articles

Efficacy of apremilast in the treatment of refractory psoriasis complicated by stage 4 chronic kidney disease: a case report

Liu Zhong^1,2, Shi Zeqi¹, Deng Yunhua¹

¹Department of Dermatology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China; ²Department of Dermatology, Wuhan Hospital of Traditional Chinese and Western Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China

Received:2023-10-10 Revised:2024-03-05 Online:2024-09-15 Published:2024-09-04
Contact: Deng Yunhua E-mail:yhdeng@tjmu.edu.cn
Supported by:
Knowledge Innovation Project of the Wuhan Science and Technology Bureau （2022020801020528）; Beijing Science and Innovative Medicine Development Foundation Project （KC2022-JX-0165）

Abstract

Liu Zhong, Shi Zeqi, Deng Yunhua. Efficacy of apremilast in the treatment of refractory psoriasis complicated by stage 4 chronic kidney disease: a case report[J]. Chinese Journal of Dermatology, 2024, 57(9): 844-845.doi:10.35541/cjd.20230580

References ［7］

［1］	Armstrong AW, Read C. Pathophysiology, clinical presentation, and treatment of psoriasis: a review［J］. JAMA, 2020,323（19）:1945⁃1960. doi: 10.1001/jama.2020.4006.
［2］	Poole RM, Ballantyne AD. Apremilast: first global approval［J］. Drugs, 2014,74（7）:825⁃837. doi: 10.1007/s40265⁃014⁃0218⁃4.
［3］	Nast A, Smith C, Spuls PI, et al. EuroGuiDerm guideline on the systemic treatment of psoriasis vulgaris ⁃ part 1: treatment and monitoring recommendations［J］. J Eur Acad Dermatol Venereol, 2020,34（11）:2461⁃2498. doi: 10.1111/jdv.16915.
［4］	Mrowietz U, Barker J, Conrad C, et al. Efficacy and safety of apremilast in patients with limited skin involvement, plaque psoriasis in special areas and impaired quality of life: results from the EMBRACE randomized trial［J］. J Eur Acad Dermatol Venereol, 2023,37（2）:348⁃355. doi: 10.1111/jdv.18689.
［5］	Rich P, Gooderham M, Bachelez H, et al. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with difficult⁃to⁃treat nail and scalp psoriasis: results of 2 phaseⅢ randomized, controlled trials （ESTEEM 1 and ESTEEM 2）［J］. J Am Acad Dermatol, 2016,74（1）:134⁃142. doi: 10.1016/j.jaad.2015.09.001.
［6］	Nguyen CM, Leon A, Danesh M, et al. Improvement of nail and scalp psoriasis using apremilast in patients with chronic psoriasis: phase 2b and 3, 52⁃week randomized, placebo⁃controlled trial results［J］. J Drugs Dermatol, 2016,15（3）:272⁃276.
［7］	Ghamrawi RI, Ghiam N, Wu JJ. Comparison of psoriasis guidelines for use of apremilast in the United States and Europe: a critical appraisal and comprehensive review［J］. J Dermatolog Treat, 2022,33（1）:94⁃99. doi: 10.1080/09546634.2020.1770176.

Efficacy of apremilast in the treatment of refractory psoriasis complicated by stage 4 chronic kidney disease: a case report

PDF

PDF (Mobile)

Knowledge

Abstract

Cite this article

share this article

References ［7］

Related Articles 0

Metrics

Comments

Recommended 10